

- U.S. Department of Health and Human Services. *The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General*. Atlanta: Author; 2014.
- Colditz GA, Wei EK. Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality. *Annu Rev Public Health* 2012;33:137–156.
- Lynch SM, Rebbeck TR. Bridging the gap between biologic, individual, and macroenvironmental factors in cancer: a multilevel approach. *Cancer Epidemiol Biomarkers Prev* 2013;22:485–495.
- Rahman N. Realizing the promise of cancer predisposition genes. *Nature* 2014;505:302–308.
- Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000;343:78–85.
- Hunter DJ, Chanock SJ. Genome-wide association studies and “the art of the soluble.” *J Natl Cancer Inst* 2010;102:836–837.
- Luch A. Nature and nurture—lessons from chemical carcinogenesis. *Nat Rev Cancer* 2005;5:113–125.
- Taddei ML, Giannoni E, Comito G, et al. Microenvironment and tumor cell plasticity: an easy way out. *Cancer Lett* 2013;341:80–96.
- Fessler E, Dijkstra FE, De Sousa E Melo, et al. Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? *Cancer Lett* 2013;341:97–104.
- Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell* 2012;21:309–322.
- Irigaray P, Belpomme D. Basic properties and molecular mechanisms of exogenous chemical carcinogens. *Carcinogenesis* 2010;31:135–148.
- Xia HJ, Chen CS. Progress of non-human primate animal models of cancers. *Dongwuxue Yanjiu* 2011;32:70–80.
- Yi C, He C. DNA repair by reversal of DNA damage. *Cold Spring Harb Perspect Biol* 2013;5:a012575.
- Dizdaroglu M. Oxidatively induced DNA damage: mechanisms, repair and disease. *Cancer Lett* 2012;327:26–47.
- Wogan GN, Hecht SS, Felton JS, et al. Environmental and chemical carcinogenesis. *Semin Cancer Biol* 2004;14:473–486.
- Baan R, Grosse Y, Straif K, et al. A review of human carcinogens—Part F: chemical agents and related occupations. *Lancet Oncol* 2009;10:1143–1144.
- Rendic S, Guengerich FP. Contributions of human enzymes in carcinogen metabolism. *Chem Res Toxicol* 2012;25:1316–1383.
- Luch A. The mode of action of organic carcinogens on cellular structures. *EXS* 2006;65–95.
- Anttila S, Raunio H, Hakkola J. Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis. *Am J Respir Cell Mol Biol* 2011;44:583–590.
- Pogribny IP, Beland FA. DNA methylome alterations in chemical carcinogenesis. *Cancer Lett* 2012 [Epub ahead of print].
- Shrivastav N, Li D, Essigmann JM. Chemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylation. *Carcinogenesis* 2010;31:59–70.
- Kew MC. Aflatoxins as a cause of hepatocellular carcinoma. *J Gastrointest Liver Dis* 2013;22:305–310.
- Feng Z, Hu W, Hu Y, et al. Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair. *Proc Natl Acad Sci U S A* 2006;103:15404–15409.
- Porta M, Crous-Bou M, Wark PA, et al. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. *Mutat Res* 2009;682:83–93.
- Blackford A, Parmigiani C, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. *Cancer Res* 2009;69:3681–3688.
- Eastmond DA, Vulimiri SV, French JE, et al. The use of genetically modified mice in cancer risk assessment: challenges and limitations. *Crit Rev Toxicol* 2013;43:611–631.
- Boverhof DR, Chamberlain MP, Elcombe CR, et al. Transgenic animal models in toxicology: historical perspectives and future outlook. *Toxicol Sci* 2011;121:207–233.
- Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. *J Pharmacol Exp Ther* 2008;327:288–299.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646–674.
- Demant P. Cancer susceptibility in the mouse: genetics, biology and implications for human cancer. *Nat Rev Genet* 2003;4:721–734.
- Klatt P, Serrano M. Engineering cancer resistance in mice. *Carcinogenesis* 2003;24:817–826.
- Lynch D, Svoboda J, Putta S, et al. Mouse skin models for carcinogenic hazard identification: utilities and challenges. *Toxicol Pathol* 2007;35:853–864.
- Lash LH, Hines RN, Gonzalez FJ, et al. Genetics and susceptibility to toxic chemicals: do you (or should you) know your genetic profile? *J Pharmacol Exp Ther* 2003;305:403–409.
- Di PC, Magno LA, Rios-Santos F. Glutathione S-transferases: an overview in cancer research. *Expert Opin Drug Metab Toxicol* 2010;6:153–170.
- Feng S, Cao Z, Wang X. Role of aryl hydrocarbon receptor in cancer. *Biochim Biophys Acta* 2013;1836:197–210.
- Jiang XL, Gonzalez FJ, Yu AM. Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. *Drug Metab Rev* 2011;43:27–40.
- Tuna M, Amos CI. Genomic sequencing in cancer. *Cancer Lett* 2013;340:161–170.
- MacConaill LE. Existing and emerging technologies for tumor genomic profiling. *J Clin Oncol* 2013;31:1815–1824.
- Watson IR, Takahashi K, Futreal PA, et al. Emerging patterns of somatic mutations in cancer. *Nat Rev Genet* 2013;14:703–718.
- Dumas ME. Metabolome 2.0: quantitative genetics and network biology of metabolic phenotypes. *Mol Biosyst* 2012;8:2494–2502.
- Adamski J, Sulre K. Metabolomics platforms for genome wide association studies—linking the genome to the metabolome. *Curr Opin Biotechnol* 2013;24:39–47.
- Verma M, Khoury MJ, Ioannidis JP. Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling. *Cancer Epidemiol Biomarkers Prev* 2013;22:189–200.
- Edwards SL, Beesley J, French JD, et al. Beyond GWAS: illuminating the dark road from association to function. *Am J Hum Genet* 2013;93:779–797.
- Di LG, Garofalo M, Croce CM. MicroRNAs in cancer. *Annu Rev Pathol* 2014;9:287–314.
- Cheetham SW, Gruhl F, Mattick JS, et al. Long noncoding RNAs and the genetics of cancer. *Br J Cancer* 2013;108:2419–2425.
- Izzotti A, Pulliero A. The effects of environmental chemical carcinogens on the microRNA machinery. *Int J Hyg Environ Health* 2014 [Epub ahead of print].
- Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of *Fusobacterium* with colorectal carcinoma. *Genome Res* 2012;22:292–298.
- Compare D, Nardone G. Contribution of gut microbiota to colonic and extracolonic cancer development. *Dig Dis* 2011;29:554–561.
- Ahn J, Chen CY, Hayes RB. Oral microbiome and oral and gastrointestinal cancer risk. *Cancer Causes Control* 2012;23:399–404.
- Schwabe RF, Jobin C. The microbiome and cancer. *Nat Rev Cancer* 2013;13:800–812.
- Wild CP, Scalbert A, Herceg Z. Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. *Environ Mol Mutagen* 2013;54:480–499.
- Brennan K, Flanagan JM. Epigenetic epidemiology for cancer risk: harnessing germline epigenetic variation. *Methods Mol Biol* 2012;863:439–465.
- Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. *N Engl J Med* 2010;362:986–993.
- Boffetta P, van der Hel O, Norppa H, et al. Chromosomal aberrations and cancer risk: results of a cohort study from Central Europe. *Am J Epidemiol* 2007;165:36–43.
- Yuan JM, Gao YT, Wang R, et al. Urinary levels of volatile organic carcinogen and toxicant biomarkers in relation to lung cancer development in smokers. *Carcinogenesis* 2012;33:804–809.
- Wogan GN, Kensler TW, Groopman JD. Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess* 2012;29:249–257.
- Hatsukami DK, Benowitz NL, Rennard SI, et al. Biomarkers to assess the utility of potential reduced exposure tobacco products. *Nicotine Tob Res* 2006;8:599–622.
- Yuan JM, Gao YT, Murphy SE, et al. Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. *Cancer Res* 2011;71:6749–6757.
- Turesky RJ, Le ML. Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. *Chem Res Toxicol* 2011;24:1169–1214.
- Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol* 2013;63:234–241.
- Besaratinia A, Tommasi S. Genotoxicity of tobacco smoke-derived aromatic amines and bladder cancer: current state of knowledge and future research directions. *FASEB J* 2013;27:2090–2100.
- International Agency for Research on Cancer. *IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans: Some Non-Heterocyclic Polycyclic Aromatic Hydrocarbons and Some Related Exposures*. Volume 92. Lyon, France: World Health Organization; 2010.
- Boffetta P, Autier P, Boniol M, et al. An estimate of cancers attributable to occupational exposures in France. *J Occup Environ Med* 2010;52:399–406.
- Mordukhovich I, Rossner P Jr, Terry MB, et al. Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors. *Environ Health Perspect* 2010;118:511–518.
- Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. *Oncogene* 2002;21:7435–7451.

66. Pfeifer GP, Hainaut P. On the origin of G → T transversions in lung cancer. *Mutat Res* 2003;526:39–43.
67. Sjaastad AK, Jorgensen RB, Svendsen K. Exposure to polycyclic aromatic hydrocarbons (PAHs), mutagenic aldehydes and particulate matter during pan frying of beefsteak. *Occup Environ Med* 2010;67:228–232.
68. Hussain SP, Amstad P, Raja K, et al. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. *Cancer Res* 2001;61:6350–6355.
69. Loomis D, Grosse Y, Lauby-Secretan B, et al. The carcinogenicity of outdoor air pollution. *Lancet Oncol* 2013;14:1262–1263.
70. Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). *Lancet Oncol* 2013;14:813–822.
71. Demetriou CA, Raaschou-Nielsen O, Loft S, et al. Biomarkers of ambient air pollution and lung cancer: a systematic review. *Occup Environ Med* 2012;69:619–627.
72. Galbraith D, Gross SA, Paustenbach D. Benzene and human health: A historical review and appraisal of associations with various diseases. *Crit Rev Toxicol* 2010;40:1–46.
73. Vlaanderen J, Portengen L, Rothman N, et al. Flexible meta-regression to assess the shape of the benzene-leukemia exposure-response curve. *Environ Health Perspect* 2010;118:526–532.
74. Vlaanderen J, Lan Q, Kromhout H, et al. Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. *Am J Ind Med* 2012;55:779–785.
75. Snyder R. Leukemia and benzene. *Int J Environ Res Public Health* 2012;9:2875–2893.
76. Grollman AP. Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. *Environ Mol Mutagen* 2013;54:1–7.
77. Hollstein M, Moriya M, Grollman AP, et al. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. *Mutat Res* 2013;753:41–49.
78. Stiborova M, Martinek V, Frei E, et al. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. *Curr Drug Metab* 2013;14:695–705.
79. Attaluri S, Bonala RR, Yang IY, et al. DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. *Nucleic Acids Res* 2010;38:339–352.
80. Sidorenko VS, Yeo JE, Bonala RR, et al. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. *Nucleic Acids Res* 2012;40:2494–2505.
81. Nedelko T, Arlt VM, Phillips DH, et al. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. *Int J Cancer* 2009;124:987–990.
82. Hoang ML, Chen CH, Sidorenko VS, et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. *Sci Transl Med* 2013;5:197ra102.
83. Poon SL, Pang ST, McPherson JR, et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. *Sci Transl Med* 2013;5:197ra101.